share_log

東証グロ-ス指数は大幅反発、新興株に物色向かう

The Tokyo Stock Exchange Growth Index saw a significant rebound, with a shift of interest towards emerging stocks.

Fisco Japan ·  Nov 19 15:58

Tokyo Stock Exchange growth market index 808.64 +14.59 / volume 0.2 billion 15.63 million shares / trading value 120.7 billion yen.

Tokyo Stock Exchange growth market 250 index 631.21 +11.95 / volume 86.49 million shares / trading value 89.1 billion yen.

Today in the growth market, the Tokyo Stock Exchange growth market index and the Tokyo Stock Exchange growth market 250 index saw a significant rebound, with 387 rising stocks, 161 declining stocks, and 43 unchanged.

The growth market had a steady performance today. The previous day on the 18th, the US market's dow inc continued to decline. The unexpectedly improved November NAHB residence market index and persistent growth expectations supported it, but the dow faced profit-taking sell-offs and trended softly throughout the day. The nasdaq rose supported by the surge in electric vehicle manufacturers, Tesla (TSLA), and the decline in long-term interest rates, with buying driven by expectations around the earnings reports of semiconductors nvidia (NVDA).

Amid a mixed US stock market, the Tokyo Stock Exchange growth market index rebounded at the start. After widening its gains in the morning, the positive trend continued with strong buying. Even in the afternoon, the market remained in a high trading range, closing the day in positive territory. The Nikkei average and TOPIX also stayed in positive territory, however, concerns over US-China relations due to the potential actions of the upcoming Trump administration made large caps harder to trade, and buying interest shifted to emerging stocks that seemed to have been lagging. Additionally, after the earnings reports circulated, attention focused on individual stocks showing favorable earnings and materials.

In individual stocks, de western therapeutics institute <4576>, which announced results regarding the late-stage phase 2 clinical trial for glaucoma treatments, saw a rise of 44% to hit the daily limit. Eltes <3967>, which announced a shareholder benefit for its 20th anniversary, also saw a rise of 17% to reach the daily limit. Furthermore, GMO Financial Gate <4051>, which announced a share buyback, rose by 15%. Among the top market capitalization stocks, lifenet <7157> and cover <5253> performed steadily, while the highest gainers included renewable japan <9522>, agile <6573>, and BBD initiative <5259>.

On the other hand, continuingly favored by selling, quolis <4894> saw a drop of 15% to top the decliners, while schoo <264A>, which had recently surged, dropped by 7% due to dominant profit-taking. Additionally, blue innovation <5597>, which had surged the previous day, also fell by 4% due to profit-taking. Among the top market capitalization stocks, trial <141A> and genda <9166> trended softly, while the largest decliners included cellseed <7776>, thecoo <4255>, and cyber buzz <7069>.

In the Tokyo Stock Exchange growth market core index, stocks like lifenet, cover, and tymy <215A> rose.


[Top 10 gainers and losers on the Tokyo Stock Exchange Growth Market]

Top 10 gainers

koss corpStock SymbolCurrent PriceChange from Previous DayRatio compared to the previous period
19522Renewable J124650868.83
24576DWTI973044.78
36573Agile1233032.26
43967Eltes65910017.89
55259BBDI118716716.37
6241AROXX140519516.12
74884Kringl90412415.90
89236Japan M&A111615015.53
94051GMO-FG7510100015.36
10260AOrts5737314.60

Top 10 declining percentage | Code | Stock name | Current price | Previous day difference | Previous ratio |

koss corpStock SymbolCurrent PriceChange from Previous DayRatio compared to the previous period
14894Quorips4275-785-15.51
27048Beltora302-30-9.04
3264ASchoo962-74-7.14
47776Cellseed495-36-6.78
54255THECOO716-49-6.41
6269ASapeet3205-200-5.87
77069Cyber Buzz726-38-4.97
85597Blue Innovate770-38-4.70
9244AGrowth Experience2349-109-4.43
104069BlueMeme920-37-3.87
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment